Schizophrenia Therapeutics Market Size (7MM) was more than USD 8 Billion in 2025 and is projected to grow at a significant CAGR by 2036, estimates DelveInsight

DelveInsight's "Schizophrenia Market Insights, Epidemiology, and Market Forecast-2036" report delivers an in-depth understanding of Schizophrenia, historical and forecasted epidemiology, as well as the Schizophrenia market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Discover Key Insights into the Schizophrenia Market with DelveInsight's In-Depth Report @ Schizophrenia Market Size- https://www.delveinsight.com/sample-request/schizophrenia-market?utm_source=open&utm_medium=pr&utm_campaign=kkpr

Key Takeaways from the Schizophrenia Market Report

• In February 2026, the US FDA accepted Teva Pharmaceutical Industries's New Drug Application (NDA) for its investigational drug, olanzapine extended-release injectable suspension (TEV-'749), which is intended for once-monthly treatment of schizophrenia in adults.
• In January 2026, Reviva announced publication on clinical vocal biomarker data from the RECOVER Phase III clinical trial of brilaroxazine to treat negative symptoms in schizophrenia.
• In December 2025, The FDA recommended that Reviva conduct a second Phase III clinical trial of brilaroxazine in patients with schizophrenia to generate additional efficacy data and to expand the safety database. Reviva plans to initiate the RECOVER-2 Phase III trial in the first half of 2026.
• In December 2025, Teva filed an FDA NDA for its once-monthly olanzapine extended-release injectable, supported by Phase III SOLARIS data demonstrating sustained efficacy, safety, tolerability, and potential adherence benefits for adults with schizophrenia.
• According to DelveInsight's estimates, in 2025, the total diagnosed prevalent cases of schizophrenia in the 7MM were nearly 4 million, of which the US accounted for nearly 1.5 million cases.
• Among the 7MM in 2025, EU4 and the UK accounted for nearly 42% of the total diagnosed prevalent cases of schizophrenia.
• DelveInsight's analysis suggests that males have a higher susceptibility to schizophrenia. In 2025, the diagnosed prevalence in the US was approximately 780,000 for males and 670,000 for females.
• In 2025, among EU4 and the UK, the diagnosed prevalent cases categorized by severity accounted for approximately 380,000, 600,000, and 640,000 cases for mild, moderate, and severe severity levels respectively.
• The leading Schizophrenia companies such as Sumitomo Pharma, Otsuka Pharmaceuticals, Reviva Pharmaceuticals, Minerva Neurosciences, Mitsubishi Tanabe Pharma, Bristol Myers Squibb, Teva Pharmaceutical, MedinCell, Lyndra Therapeutics, Neurocrine Biosciences, Newron Pharmaceuticals, and others.
• Promising Schizophrenia Therapies such as Ulotaront (SEP-363856), Brilaroxazine (RP5063), Olanzapine LAI (TEV-'749), Roluperidone (MIN-101), Valbenazine (NBI-98854), LYN-005, Evenamide (NW-3509), and others.

Stay ahead in the Schizophrenia Therapeutics Market with DelveInsight's Strategic Report @ Schizophrenia Market Outlook- https://www.delveinsight.com/sample-request/schizophrenia-market?utm_source=open&utm_medium=pr&utm_campaign=kkpr

Schizophrenia Epidemiology Segmentation in the 7MM

• Total Prevalent Cases of Schizophrenia
• Total Diagnosed Cases of Schizophrenia
• Gender-specific Cases of Schizophrenia
• Severity-specific Cases of Schizophrenia
• Age-specific Treated Cases of Schizophrenia
• Total Treated Cases of Schizophrenia

Download the report to understand which factors are driving Schizophrenia epidemiology trends @ Schizophrenia Prevalence- https://www.delveinsight.com/sample-request/schizophrenia-market?utm_source=open&utm_medium=pr&utm_campaign=kkpr

Schizophrenia Pipeline Analysis

• Ulotaront (SEP-363856): Sumitomo Pharma/Otsuka Pharmaceuticals
Ulotaront (SEP-363856) is a trace amine-associated receptor 1 (TAAR1) agonist with serotonin 5-HT1A agonist activity, jointly developed by Sunovion Pharma and PsychoGenics. It is a small-molecule oral agent that does not bind to dopamine D2 or serotonin 5-HT2A receptors. Sunovion discovered Ulotaront in collaboration with PsychoGenics using its in vivo phenotypic SmartCube platform and associated artificial intelligence algorithms. In May 2019, the US FDA granted Breakthrough Therapy Designation for SEP-363856 for the treatment of people with schizophrenia. The drug is expected to enter the US market in 2028.
• Brilaroxazine (RP5063): Reviva Pharmaceuticals
Brilaroxazine (RP-5063) is a new chemical entity with potent affinity and selectivity against key serotonin and dopamine receptors implicated in schizophrenia and other psychiatric disorders. RP-5063 is a multimodal modulator of the serotonin 5-HT1A, 5-HT2A, 5-HT2B, and 5-HT7 receptors and D2, D3, and D4 dopamine receptors in clinical development for multiple neuropsychiatric indications. The Phase III RECOVER-2 trial of brilaroxazine in schizophrenia is expected to begin in mid-2025, with topline results anticipated in Q3 2026 and potential NDA submission in Q4 2026.
• Olanzapine LAI (TEV-'749): Teva Pharmaceutical/MedinCell/Royalty Pharma
In February 2026, the US FDA accepted Teva Pharmaceutical Industries's New Drug Application (NDA) for its investigational drug, olanzapine extended-release injectable suspension (TEV-'749), which is intended for once-monthly treatment of schizophrenia in adults. In December 2025, Teva filed the FDA NDA supported by Phase III SOLARIS data demonstrating sustained efficacy, safety, tolerability, and potential adherence benefits for adults with schizophrenia.

Schizophrenia Drugs Market Insights

• The current treatment landscape includes second-generation antipsychotics such as REXULTI (brexpiprazole), CAPLYTA (lumateperone), LATUDA (lurasidone hydrochloride), VRAYLAR (cariprazine), ABILIFY MYCITE (aripiprazole with sensor), LYBALVI (olanzapine and samidorphan), SAPHRIS and SECUADO (asenapine), INVEGA SUSTENNA/TRINZA/HAFYERA (paliperidone palmitate), ARISTADA/ARISTADA INITIO (aripiprazole lauroxil), PERSERIS (risperidone), and FANAPT (iloperidone).
• A major recent addition is Bristol Myers Squibb's COBENFY (KarXT), which received US FDA approval in September 2024 as the first muscarinic agonist approved for schizophrenia. Recent research indicates that long-acting injectables (LAIs) may be more effective than oral medications in reducing the risk of hospitalization for schizophrenia.
• The Schizophrenia competitive landscape is undergoing dynamic changes with the approval of generic versions for drugs like LATUDA (lurasidone hydrochloride), leading to a substantial decline in its market revenue. Although established atypical antipsychotics manage positive symptoms, their efficacy varies, and they have a limited impact on cognitive and negative symptoms, creating opportunities for novel therapies.

Get In-Depth Knowledge on Schizophrenia Market Trends and Forecasts with DelveInsight @ Schizophrenia Treatment Market- https://www.delveinsight.com/sample-request/schizophrenia-market?utm_source=open&utm_medium=pr&utm_campaign=kkpr

Schizophrenia Companies

Boehringer Ingelheim, Sumitomo Pharma, Otsuka Pharmaceuticals, Reviva Pharmaceuticals, Minerva Neurosciences, Mitsubishi Tanabe Pharma, Karuna Therapeutics, Bristol Myers Squibb, Royalty Pharma, Acadia Pharmaceuticals, Rovi Pharmaceuticals Laboratories, Teva Pharmaceutical, MedinCell, Lyndra Therapeutics, Neurocrine Biosciences, Luye Pharma, Newron Pharmaceuticals, and others.

Schizophrenia Market Outlook

Schizophrenia is a severe and chronic mental disorder affecting about 1% of Americans, impacting thinking, emotions, decision-making, and social interaction. At present, there is no cure for schizophrenia, and treatment primarily focuses on managing symptoms and preventing relapses. The mainstay of treatment includes medication and psychosocial therapy. Pharmacological therapy plays a vital role, with many mono and combination pharmacological therapies available for treating schizophrenia symptoms.
Antipsychotic drugs, categorized into first and second generations, dominate the market. Notably, second-generation antipsychotics (SGA) are favored over their first-generation (FGA) counterparts. The market size of schizophrenia in the 7MM was more than USD 8 billion in 2025, which is further expected to increase by 2036. Among the 7MM, in 2025 the US accounted for the largest market size of nearly USD 6 billion.

Scope of the Schizophrenia Market Report

• Coverage- 7MM
• Study Period- 2022-2036
• Forecast Period- 2026-2036
• Schizophrenia Companies- Boehringer Ingelheim, Sumitomo Pharma, Otsuka Pharmaceuticals, Reviva Pharmaceuticals, Minerva Neurosciences, Mitsubishi Tanabe Pharma, Bristol Myers Squibb, Teva Pharmaceutical, MedinCell, Lyndra Therapeutics, Neurocrine Biosciences, Newron Pharmaceuticals, and others
• Schizophrenia Therapies- Ulotaront (SEP-363856), Brilaroxazine (RP5063), Olanzapine LAI (TEV-'749), Roluperidone (MIN-101), Valbenazine (NBI-98854), LYN-005, Evenamide (NW-3509), and others
• Schizophrenia Market Access & Reimbursements, Unmet Needs and Perspectives
• Schizophrenia SWOT Analysis and KOL Views

Unlock Strategic Insights with DelveInsight's Comprehensive Schizophrenia Market Report @ Schizophrenia Market Drivers and Barriers- https://www.delveinsight.com/sample-request/schizophrenia-market?utm_source=open&utm_medium=pr&utm_campaign=kkpr

Table of Contents

1. Key Insights
2. Report Introduction
3. Schizophrenia Market Overview at a Glance
4. Methodology of Schizophrenia Epidemiology and Market
5. Executive Summary of Schizophrenia
6. Key Events
7. Disease Background and Overview
8. Patient Journey
9. Epidemiology and Patient Population
10. Marketed Drugs
11. Emerging Drugs
12. Schizophrenia: Market Analysis
13. Key Opinion Leaders' Views
14. SWOT Analysis
15. Unmet Needs
16. Market Access and Reimbursement
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

Company Name: DelveInsight Business Research LLP
Contact Person: Kanishk Kumar
Email: kkumar@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

This release was published on openPR.